Sandoz enters into biosimilar partnership with Biocon

Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.

Sandoz, a division of Novartis, will focus on commercialisation in North American and the EU, while India-based biotherapeutics company Biocon will focus on the rest of the world.

Richard Francis, CEO of Sandoz, said that the partnership will boost Sandoz’s reputation in the biosimilars sector and will help position the company to “lead well into the future”.

The press release, which was issued on Thursday, January 18, noted that there was no guarantee of the products’ commercial success.

Sandoz currently markets five biosimilars worldwide.

Biocon is the first Indian company to have a biosimilar approved by the US Food and Drug Administration.

Together with US-based Mylan, Biocon developed a biosimilar to treat breast cancer and stomach cancers. According to   , the drug will be sold under the name Ogivri.

LSIPR reported in May 2017 that Sandoz had entered into a development and commercialisation agreement with US-based drug research company Durect to develop the drug Posimir (saber-bupivacaine).

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.